

# **DROP-CRE Advisory Committee**

## **Agenda**



History, goals, and objectives



Membership housekeeping



Epi update





# DROP-CRE History, Goals, and Objectives

# Drug-Resistant Organism Prevention and Coordinated Regional Epidemiology Network (DROP-CRE)



**History** 

Public health academic partnership Initiated September 2012



Goals

Detect and contain high-priority antimicrobial resistant pathogens

# Drug-Resistant Organism Prevention and Coordinated Regional Epidemiology Network (DROP-CRE)



Monitor Oregon antimicrobial resistant organism epidemiology and assess needs for prevention and response



Coordinate statewide education about carbapenem-resistant and other antimicrobial resistant (AR) organisms




Develop laboratory capacity and promote consistent laboratory practices for the rapid detection of carbapenemase-producing and other AR organisms



Provide outbreak assistance

#### **DROP-CRE** focuses on emerging pathogen threats



## DROP-CRE focuses on emerging pathogen threats

#### Candida auris



Candida auris source: CDC

#### **Carbapenemase producing organisms (CPOs)**



Carbapenem-resistant Klebsiella pneumoniae




# Housekeeping / Membership

## **DROP-CRE Advisory Committee Membership**


- Minimum advisory committee commitment:
  - 1 annual meeting (virtual), 2 years of participation
  - May be asked for contributions to resources, guidance documents, etc. as needed and available
  - Smaller group of OHA staff and consultants meets monthly to carry out this work
- 2025 = renewal year

#### **Current DROP-CRE Invitees**



OR Region	% invitees (N=26)
Region 1	54%
Region 2	8%
Region 3	4%
Region 5	4%
Region 6	0%
Region 7	8%
Region 9	8%
Statewide	15%
Total	100%

#### **Current DROP-CRE Invitees**






## Survey # 1



# High-priority MDROs Epi Update

## DROP-CRE focuses on emerging pathogen threats

#### Candida auris



Candida auris

#### **Carbapenemase producing organisms (CPOs)**



Carbapenem-resistant *Klebsiella pneumoniae* 

## Carbapenemase production varies by organism



#### Carbapenem-resistant *Enterobacterales* (CRE)

- Reportable since 2010
- 1639 cases since 2010
- approx. 8% CPO over past 5 years (n=91 since 2010)



#### Carbapenem-resistant Pseudomonas aeruginosa (CRPA)

- Not reportable; voluntary submission of isolates for CPO testing
- 498 isolates since 2019
- <1% CPO (n=5)




#### Carbapenem-resistant Acinetobacter (CRA)


- Newly reportable in October 2023; regional CR-A. baumannii surveillance in Portland area since 2011
- 65 cases since 2011
- approx. 75% CPO

## Oregon remains a low prevalence state for CPOs






#### Oregon remains a low prevalence state for CPOs




### CP-CRE as % of CRE low but increasing in Oregon

Percent of CRE isolates identified by OR laboratories that are carbapenemase producing, 2020-2024



#### **CPOs are rare in Oregon, but increasing**



#### CDC reports national increase in pediatric CPOs

# CDC reported increase in pediatric CPO consultations in 2023

- Including outbreaks in high acuity pediatric settings
- ~30% in NICU, also PICU, transplant, and burn units
- Most index cases had history of international travel or healthcare

#### OHA participating in CDC special project

Chart review concluding Nov 2024

### Oregon had first pediatric CPO case in 2023




## DROP-CRE focuses on emerging pathogen threats

#### Candida auris



Candida auris


#### **Carbapenemase producing organisms (CPOs)**



Carbapenem-resistant *Klebsiella pneumoniae* source: CDC

## Candida auris has spread quickly across the US







Powered by Bing © GeoNames, Microsoft, TomTom

#### Candida auris has spread quickly across the US






#### Candida auris has spread quickly across the US



#### Candida auris remains rare in Oregon

Candida auris cases identified in Oregon residents, Dec 2021 - Oct 2024





# High-priority MDROs Prevention Program Overview



- Provided on request
- Proactive and responsive ICARs
- Updated materials
- Project Firstline
- Newsletter
- Crosscutting



- Proactive and responsive ICARs
- Dedicated staff
- IPC learning collaboratives



- Robust routine
- Expanding capacity
- ARLN partnership
- Routine PPS
- Admission screening
- Wastewater
- CDC special projects



- Required by law
- HIE/Collective
- Reinforced frequently



- Honor roll
- ORASN
- AWARE
- LTC collaborative



- Virtual or on-site presentations on request to all facility types
- Updated guidance and education materials
  - Project Firstline MDRO printable materials (available soon)
  - Updated CRE investigative guidelines published Oct 2024
  - OHA CRO Toolkit published 2023
  - Website
  - Lab posters
  - Translations into multiple languages
- Quarterly <u>newsletter</u>
- Lab consortium
- Crosscutting education incorporated into all prevention and response activities



- On request trainings with OHA IPs and epis
- Proactive and responsive <u>ICARs</u>
  - Approx. 84 MDRO focused since 2020
- Newly funded MDRO IP positions
- IP learning collaborative in each region

- CPO surveillance
  - All CRE and CRA tested at OSPHL for CPO
  - CRPA voluntary submission
- Emerging Infectious Pathogens (EIP) surveillance including Candida
- Expanding OSPHL testing capacity
- Public-facing dashboards (under development)



- Partnership with ARLN
- Routine PPS at influential facilities
  - 5 completed thus far
- Admission screening
  - 17+ facilities
- Wastewater surveillance
  - Planning and initial site visits this year; starting in 2025
- Participation in CDC special surveillance projects
  - E.g., pediatric case review

CRE Quarterly Report 31

- CPO surveillance
  - All CRE and CRA tested at OSPHL for CPO
  - CRPA voluntary submission
- Emerging Infectious Pathogens (EIP) surveillance including *Candida*
- Expanding OSPHL testing capacity
- Public-facing dashboards (under development)



- Partnership with ARLN
- Routine PPS at influential facilities
  - 5 completed thus far
- Admission screening
  - 17+ facilities
- Wastewater surveillance
  - Planning and initial site visits this year; starting in 2025
- Participation in CDC special surveillance projects
  - E.g., pediatric case review

CRE Quarterly Report 32

- Expanding OSPHL testing capacity
  - Added AST
  - Validating Carba R
  - Plans to add C. auris
  - WGS for characterizing regional epi
    - CRA genomic analysis
    - NDM genomic analysis (planned)



CRE Quarterly Report 33

- Interfacility transfer notice required by OR law
- Reinforced in every guidance document, consultation, ICAR, response, etc.
- Health Information Exchange/Collective



- New <u>antimicrobial stewardship honor roll program</u>
- Oregon Antibiotic Stewardship Network (<u>ORASN</u>) hospital engagement
- Antibiotic use analyses using APAC data for outpatient and telehealth providers
- Oregon Alliance Working for Antibiotic Resistance Education (<u>AWARE</u>)
   Coalition for community engagement and education
- Longterm care facility collaborative scheduled to start Jan 2025





- Provided on request
- Proactive and responsive ICARs
- Updated materials
- Project Firstline
- Newsletter
- Crosscutting



- Proactive and responsive ICARs
- Dedicated staff
- IPC learning collaboratives



- Robust routine
- Expanding capacity
- ARLN partnership
- Routine PPS
- Admission screening
- Wastewater
- CDC special projects



- Required by law
- HIE/Collective
- Reinforced frequently



- Honor roll
- ORASN
- AWARE
- LTC collaborative



## Survey # 2



# High-priority MDROs Discharge & Transfer Notifications

#### Discharge planning and transfer notification challenges

#### **Challenges**

- Anecdotal and observed lack of notification on transfer
- Anecdotal and observed LTCF refusal to accept high priority-MDRO patients
- Scope of problem is unclear

#### **Possible solutions**

- Training for discharge planners
- Continued education and training for LTCFs
- Your ideas?



## Survey #3



# DROP-CRE Name update

#### Time for a new name

Drug Resistant Organism and Coordinated Regional Epidemiology

(DROP-CRE)

- Reflect scope of work beyond CRE
- Your ideas?



**Survey # 4 - 5** 

### Thank you

You can get this document in other languages, large print, braille or a format you prefer free of charge. Contact Sandra Hattan at <a href="mailto:Sandra.j.Hattan@oha.Oregon.gov">Sandra.j.Hattan@oha.Oregon.gov</a> or 971-673-1222 (voice/text). We accept all relay calls.

Public Health Division

Acute & Communicable Disease Prevention Section (ACDP)

Healthcare-Associated Infections (HAI) Program

General mailbox: hai@odhsoha.oregon.gov

